Startup Ortho Regenerative Technologies (CNSX:ORTH) said two new studies have validated its product’s ability to improve the repair of two distinct joint tissues – the rotator cuff tendon and articular cartilage.
The rotator cuff study results were presented yesterday at the Annual Orthopaedic Research Society meeting in Austin, Texas.
The study of Ortho RTi’s Ortho-R technology used MRI and histopathology (the microscopic examination of biological tissues in very fine detail), read by blinded experts, to compare the results of Ortho-R versus standard of care in a non-clinical rotator cuff injury model in sheep. It showed that Ortho-R improved rotator cuff healing processes in this large animal model, as revealed by MRI and trends of improved structural appearance of the tendon and enthesis at 12 weeks post-op, according to the Kirkland, Quebec-based company.
Ortho RTi’s proprietary biopolymer was designed to increase the healing rates of sports-related injuries to tendons, meniscus, ligaments, and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention, the company said.
Marc Lavertu, Ph.D, from Montreal’s École Polytechnique, highlighted the results of a dose-ranging study examining Ortho RTi’s Ortho-R technology in the biologic repair of rotator cuff injuries. Additionally, an article on a study of the company’s biologic in repairing damaged cartilage will appear in the Journal of Tissue Engineering and Regenerative Medicine.
“These are two more of our 16 peer-reviewed abstracts, posters, manuscripts and podium presentations in the last two years,” said Ortho RTi chief scientific officer Michael Buschmann, M.D. “Further, these are key publications resulting from work with experts at New York City’s renowned Hospital for Special Surgery.”
